Bayer, J&J’s Xarelto Wins EU Backing for Expanded Use
This article is for subscribers only.
Bayer AG and Johnson & Johnson won European backing to expand marketing of their blood-thinner Xarelto to a group of heart-disease patients that U.S. authorities have been reluctant to clear for use of the drug.
The European Medicines Agency’s drug advisory board today recommended Xarelto be approved to prevent heart attacks and strokes for people with acute coronary syndrome, a common condition that occurs when a clot blocks blood supply to the heart and can trigger a heart attack. The drug should be approved at 2.5 milligram dose, the panel said today in a statement on its website.